Kiniksa Pharmaceuticals International, plc Stock Price, News & Analysis

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with GRAMMY Award-winning singer-songwriter Carly Pearce to expand its Life DisRPted™ campaign, focusing on raising awareness for recurrent pericarditis. The campaign aims to promote early diagnosis and treatment of this rare, chronic autoinflammatory disease. Pearce, who was diagnosed with recurrent pericarditis while on tour in May 2024, joins the initiative to support patients and caregivers affected by the condition.

The campaign serves as a platform to encourage both patients and healthcare providers to recognize signs of recurrent pericarditis and develop appropriate treatment plans to minimize its impact on patients' lives. More information about the campaign and the condition can be found at LifeDisRPted.com.

Kiniksa Pharmaceuticals International (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, October 29, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. The live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com.

Individuals interested in participating via telephone can register online to receive dial-in information. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with NHL Hall-of-Famer Henrik Lundqvist to launch the Life DisRPted campaign, focusing on raising awareness of recurrent pericarditis. This national initiative aims to promote early diagnosis and treatment of this painful, debilitating chronic autoinflammatory disease.

Lundqvist, diagnosed with recurrent pericarditis in 2021, shares his personal journey in a video titled 'Comeback After Comeback'. The campaign website, LifeDisRPted.com, features this video along with a downloadable Doctor Discussion Guide to help patients communicate with healthcare providers.

Dr. Antonio Abbate, Professor of Cardiology at The University of Virginia, emphasizes the importance of early diagnosis and proactive collaboration with healthcare providers in managing recurrent pericarditis. The campaign seeks to support patients, reduce feelings of isolation, and encourage self-advocacy in disease management.

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 4, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access a live webcast of Kiniksa's presentation through the Investors & Media section of the company's official website at www.kiniksa.com. For those unable to attend the live event, a replay will be made available on Kiniksa's website within approximately 48 hours after the presentation concludes.

Kiniksa Pharmaceuticals reported strong Q2 2024 financial results, with ARCALYST net product revenue of $103.4 million, representing 90% year-over-year growth. The company increased its 2024 ARCALYST revenue guidance to $405-$415 million. Key highlights include:

1. Approximately 11% of the 14,000 multiple-recurrence target population actively on ARCALYST treatment.
2. Average total duration of ARCALYST therapy increased to ~26 months.
3. Enrollment began in the abiprubart Phase 2b trial for Sjögren's Disease.
4. Total revenue for Q2 2024 was $108.6 million.
5. Net loss for Q2 2024 was $3.9 million.
6. Cash position of $218.8 million with no debt as of June 30, 2024.

Kiniksa expects to remain cash flow positive on an annual basis, with abiprubart's clinical development fully funded in the current operating plan.

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Interested individuals can register for telephone participation, and upon registration, will receive confirmation details including a unique passcode and registrant ID. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.

Kiniksa Pharmaceuticals has begun enrolling patients in a Phase 2b clinical trial for abiprubart, a humanized anti-CD40 monoclonal antibody, aimed at treating Sjögren’s Disease, a debilitating autoimmune disorder. The trial will assess the efficacy of abiprubart administered biweekly and monthly via subcutaneous injections over a 24-week period, involving around 201 participants. The primary measure of success is the change in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) compared to a placebo. The study will also include a long-term extension phase where all participants receive active treatment. Importantly, Kiniksa expects to remain cash flow positive during this development.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a partnership with NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis. This campaign, starting in September, aims to share experiences from the recurrent pericarditis community and provide resources for patients and caregivers. Recurrent pericarditis is characterized by severe inflammation of the pericardial tissue, leading to sharp chest pain often mistaken for a heart attack. The disease significantly impacts patients' quality of life and physical wellbeing. CEO Sanj K. Patel emphasized the need for increased disease understanding to prevent delayed diagnosis and treatment. More information can be found at whatispericarditis.com and arcalyst.com.

Kiniksa Pharmaceuticals announced its sponsorship of the American Heart Association's Addressing Recurrent Pericarditis initiative on June 17, 2024. This initiative aims to enhance care for recurrent pericarditis patients through improved diagnosis and treatment practices. The program will involve healthcare champions at 15 sites to identify gaps and share best practices nationwide. The initiative aims to improve patient outcomes and quality of life through education, model sharing, and collaborative research. Key sites involved include Brigham & Women’s Hospital, Cleveland Clinic, and Mayo Clinic.